Abstract Submission Deadline: March 28, 2026 - Don’t miss out – Early Bird Registration March 31, 2026 - Submit your abstract and secure your spot today!
Abstract Submission Deadline: March 28, 2026 - Don’t miss out – Early Bird Registration March 31, 2026 - Submit your abstract and secure your spot today!
The 3rd European Cancer and Oncology Congress, scheduled for September 14–15, 2026 in London, U.K, will be a premier forum for advancing cancer science and clinical care. Designed to foster collaboration and innovation, the event will convene oncologists, scientists, healthcare professionals, nurses, and researchers from across Europe and beyond to exchange knowledge, discuss new findings, and spotlight transformative developments in oncology.
Attendees can look forward to a rich and engaging program featuring high-impact keynote sessions from world-renowned experts, thought-provoking symposia, interactive workshops, and research poster showcases. The congress will delve into critical areas including precision oncology, immunotherapy, emerging treatment strategies, survivorship, palliative and supportive care, and the integration of digital tools and AI into oncology practice. Set against the stunning backdrop of London, this event offers an inspiring environment to connect, learn, and drive progress in cancer care.
Abstract Submission Deadline: March 28, 2026
Early Bird Registration: March 31, 2026
Mid Term Registration: April 30, 2026
Final/Onsite Registration: September 14, 2026
GermanOncology
Germany
Weizmann Institute of Science
Israel
Phoenicia Medical Centre PMC
Lebanon
University of Toronto
Canada
251 Airforce General Hospital
Greece
N.N. Petrov National Medical Research Center of Oncology
Russia
Lebanese Society of Medical Oncology
Lebanon
Aakash Healthcare Superspeciality Hospital
India
Cell Receptor GmbH
Germany
GermanOncology
Germany
Phoenicia Medical Centre PMC
Lebanon
University of Bari Aldo Moro
Italy
Pusan National University Hospital
South korea
Chongqing University Cancer Hospital
China
University Medical Center Utrecht
Netherlands
Galaxy Medical Center
Romania
Dear Colleagues,
As an Organizing Committee Member of the 3rd European Cancer and Oncology Congress, it is my pleasure and honor to invite you to join us in London, United Kingdom, on September 14-15, 2026. This congress, themed "Empowering Global Oncology Through Innovation" aims to gather leading experts and researchers to discuss the latest advancements in cancer and oncology.
The congress will focus on health service research in oncological diseases and the questions, how quickly are new drugs used or new study results and guideline recommendations implemented and how representative are results of registration trials in the standard care settings? Scientists and researchers, but also clinicians and health care professionals should see how approaches to capture data from standard health care services can support results out of pivotal studies and answer additional open questions especially in handling of drugs or drug combinations in cases of complications and in patient-oriented administration. Additionally, the congress will be an excellent opportunity to exchange already existing and to enhance future knowledge regarding developments in oncological diseases.
So, the event will offer a premier platform for networking and collaboration to improve the velocity from research to standard care.
We look forward to welcoming you, your research team, and your colleagues to this impactful event in London.
Best Wishes,
Dr. Rainer Lipp, MD
Specialist in Internal Medicine, Hematology and Medical Oncology
Medical Lead and Co-Founder GermanOncology GmbH, Hamburg
About Oncotarget
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking diff erent fi elds of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative; 2018-2022) and Dimensions (Digital Science).
Scope
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural editorial, Introducing Oncotarget.
Homepage Link: https://www.oncotarget.com/
About Cancers
Cancers (ISSN 2072-6694, IF 4.4) is an international peer-reviewed open access journal on oncology. The journal publishes high-quality articles including basic, translational, and clinical studies on all tumour types.
The journal is indexed in Scopus, PubMed, SCIE (Web of Science), PMC, and other relevant databases. Publications enjoy high visibility and short processing times. Current journal's CiteScore is 8.8.
Homepage Link:https://www.mdpi.com/journal/cancers
About Antibodies
Antibodies (ISSN 2073-4468, IF 3.0) is an international, peer-reviewed open-access journal that provides an advanced forum for scientific publications related to antibodies and antigens. Major topics of interest include (but are not limited to): Antibodies and the humoral immune response, Discovery, generation and selection of antibodies, Antibody structure and function, Antibody engineering, conjugates and fusion proteins, Antibodies in biomedical research and therapy.
Homepage Link https://www.mdpi.com/journal/antibodies
C2P Forum is pleased to announce the successful completion of the 2nd European Meeting on Cancer and Oncology, held on November 03-04, in Prague, Czech Republic.
The conference, themed “Exploring New Horizons in Oncology and Cancer Research,” concluded with great success.
We extend our sincere gratitude to the esteemed scientists, distinguished researchers, students and professionals from universities, research institutions, companies, and laboratories worldwide who contributed their latest insights and expertise in the field of Cancer and Oncology.
The conference featured a dynamic program, including keynote addresses, oral presentations, poster sessions, video presentation and E-Poster Presentations. The event was marked by significant engagement and outstanding contributions, and we are delighted to share some of the key highlights presented during the sessions:
• Paola Dal Cin, Brigham and Women’s Hospital & Harvard Medical School, USA
• Genia Burchall, Central Queensland University, Australia
• Avigdor Scherz, The Weizmann Institute of Science, Israel
• Giacomina Brunetti, University of Bari Aldo Moro, Italy
• Silvia Scaglione, National Research Council (CNR), Italy
• Amal Assef Nasser, Phoenicia Medical Center (PMC), Lebanon
• Folinas Konstantinos, 251 Airforce General Hospital, Greece
• Martyna Pytlarz, Technical University of Denmark, Denmark
• Ch’ng You Qun, University Hospitals of Leicester NHS Trust, UK
• Laura Cerchia, Institute of Endotypes in Oncology, Metabolism and Immunology “G. Salvatore”- National Research Council (IEOMI-CNR), Italy
• Ella Fernandes, King's College London NHS Trust, UK
• Monica Fedele, Institute of Endotypes in Oncology, Metabolism and Immunology “G. Salvatore”- National Research Council (IEOMI-CNR), Italy
• Elena-Mihaela Vrabie, Fundeni Clinical Institute & Carol Davila University of Medicine and Pharmacy, Romania
• Dan Cacsire Castillo-Tong, Medical University of Vienna, Austria
• Daniel Tippner, Martin Luther University Halle-Wittenberg, Germany
• Mónica G Mendoza-Rodríguez, Universidad Nacional Autónoma de México, México
• Mike Alexander Celis Rodríguez, Universidad Industrial de Santander, Colombia
• Morsal Sabihi, University Medical Center Hamburg-Eppendorf, Germany
• Amira Mahmoud Ali Abdallah, Sheikh Shakhbout Medical City, UAE
• Ferhat Bostanci, Istanbul Sabahattin Zaim University & Yıldız Technical University, Turkey
• José Carlos Jaime-Pérez, Universidad Autónoma de Nuevo León, México
• Andrada Nemesis Crișan & Roxana Elena Sicoe, Galaxy Medical Center, Romania
• Rana Ajami, Ziv Medical Center, Israel
• Elena Bukovetzky & Mona Nassar, Ziv Medical Center, Israel
• Shivani Golem, University of Kansas Medical Center, USA
• Swapnil Surpur, Wright Center for Graduate Medical Education, USA
• Siqi Hua, Shanghai Jiao Tong University, China
• Ema Ruszova, University Hospital Bulovka, Czech Republic
We would like to express our sincere appreciation to our Session Chairs Paola Dal Cin, Brigham and Women’s Hospital & Harvard Medical School, USA, Folinas Konstantinos, 251 Airforce General Hospital, Greece, & Avigdor Scherz, The Weizmann Institute of Science, Israel
Building on the success of the Cancer Congress 2025, we are pleased to announce our upcoming event, 3rd European Cancer and Oncology Congress on September 14-15, 2026 in London, UK
More info: https://cancer.c2pforum.com/
Huge thanks to all the delegates! Your energy and involvement made this event a big success!
Mark your calendars and set your reminders.
Hope to meet you again in London, UK!!